3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
2
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Lung Neoplasms
2
Stomach Neoplasms
1
Psychological Well-Being
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Peripheral Nervous System Diseases
1
Motor Activity
1
Infections
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Arthralgia
1
Interventions
Oxaliplatin
42
Fluorouracil
27
Capecitabine
24
pembrolizumab
21
S 1 (combination)
19
Paclitaxel
19
Leucovorin
16
Nivolumab
13
Docetaxel
13
sintilimab
12
Drug Therapy
12
Trastuzumab
11
tislelizumab
10
Cisplatin
10
Irinotecan
9
Bevacizumab
8
trastuzumab deruxtecan
7
spartalizumab
7
XELOX
7
Surgical Procedures, Operative
7
Radiotherapy
7
Hyperthermic Intraperitoneal Chemotherapy
7
Biopsy
7
fludarabine
6
disitamab vedotin
6
Cyclophosphamide
6
lenvatinib
5
apatinib
5
Specimen Handling
5
Ramucirumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Stomach Neoplasms
×
Fish Oils
×
Clear all
NCT04871412
2026-01-30
POISE
Ottawa Hospital Research Institute
Phase 3
Recruiting
20 enrolled